# A Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Hematologic Malignancy

> **NCT04795128** · PHASE1 · COMPLETED · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 70 (actual)

## Conditions studied

- Hematologic Malignancy

## Interventions

- **BIOLOGICAL:** IBI322

## Key facts

- **NCT ID:** NCT04795128
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-07
- **Primary completion:** 2023-08-15
- **Final completion:** 2023-08-15
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2024-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04795128

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04795128, "A Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Hematologic Malignancy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04795128. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*